Lixte Biotechnology Holdings Files S-1/A Amendment
Ticker: LIXT · Form: S-1/A · Filed: Apr 9, 2025 · CIK: 1335105
| Field | Detail |
|---|---|
| Company | Lixte Biotechnology Holdings, INC. (LIXT) |
| Form Type | S-1/A |
| Filed Date | Apr 9, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, s-1/a, registration-statement
TL;DR
Lixte Biotech filed an S-1/A update. Looks like they're still prepping for a securities offering.
AI Summary
Lixte Biotechnology Holdings, Inc. filed an S-1/A amendment on April 9, 2025, for a registration statement. The company, previously known as SRKP 7 INC, is incorporated in Delaware and operates in the Pharmaceutical Preparations sector. Its principal executive offices are located in Pasadena, California.
Why It Matters
This filing indicates an update to Lixte Biotechnology's registration statement, which is a crucial step for companies looking to offer securities to the public or make significant changes to their existing offerings.
Risk Assessment
Risk Level: medium — S-1/A filings often relate to securities offerings, which inherently carry risks for investors due to market volatility and company-specific performance.
Key Numbers
- 333-286385 — SEC File Number (Identifies the specific registration statement)
- 25825235 — Film Number (Internal SEC processing number)
Key Players & Entities
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. (company) — Registrant
- SRKP 7 INC (company) — Former company name
- Bastiaan van der Baan (person) — Chief Executive Officer
- David L. Ficksman, Esq. (person) — Legal counsel
- TroyGould PC (company) — Legal firm
- 20250409 (date) — Filing date
FAQ
What is the primary purpose of this S-1/A filing?
This S-1/A filing is an amendment to a registration statement filed under the Securities Act of 1933, indicating updates or changes to the company's proposed securities offering or other disclosures.
When was this amendment filed with the SEC?
The amendment was filed as of April 9, 2025.
What was Lixte Biotechnology Holdings, Inc. formerly known as?
The company was formerly known as SRKP 7 INC.
Where are Lixte Biotechnology's principal executive offices located?
The principal executive offices are located at 680 East Colorado Boulevard, Suite 180, Pasadena, CA 91101.
Who is the Chief Executive Officer of Lixte Biotechnology Holdings, Inc.?
Bastiaan van der Baan is the Chief Executive Officer.
Filing Details
This Form S-1/A (Form S-1/A) was filed with the SEC on April 9, 2025 by Bastiaan van der Baan regarding LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT).